This is a multicenter pragmatic prospective observational study including Nordic hospitals treating patients with borderline resectable and locally advanced pancreatic cancer. Eligibility will be assessed at regional multidisciplinary tumor boards. Patients with borderline resectable and locally advanced (non-endocrine) pancreatic cancer according to the National Comprehensive Cancer Network (NCCN) and the International Study Group of Pancreatic Surgery (ISGPS) are eligible for inclusion. The study is observational. Quality of life will be assessed in all study participants. The primary outcomes are exploration rates, resection rates and overall survival.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed or suspected invasive pancreatic primary tumor
Tumor classified as borderline resectable or locally advanced disease according to NCCN guidelines
You may not be if
Suspected endocrine tumor
Suspected non-pancreatic periampullary tumor
Distant metastasis
Age \< 18 years
Patient unable to understand verbal or written information interfering with informed consent or treatment
Mental or organic disorder interfering with informed consent or treatments
Clareo Health | Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer
